Truist Slashes Price Target on NuCana to $20 From $150 Amid Discontinuation of NUC-3373, Keeps Buy Rating

MT Newswires10/15 19:54

A BioRxiv Medical Journal Article Has Been Published Today On Nucana "A Phosphoramidate Modification Of FUDR, NUC-3373, Causes DNA Damage And DAMPs Release From Colorectal Cancer Cells, Potentiating Lymphocyte-Induced Cell Death"

Benzinga10/12 00:23

European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading

MT Newswires09/26 23:07

Why Telesis Bio Shares Are Trading Higher By Around 110%; Here Are 20 Stocks Moving Premarket

Benzinga09/26 18:31

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States

GlobeNewswire09/26 04:01

NuCana Stock Soars 151% on Upbeat Efficacy Data From Melanoma Study

Zacks 09/17 22:35